Silencing of XB130 is associated with both the prognosis and chemosensitivity of gastric cancer.

XB130 is a newly characterized adaptor protein that was reported to promote thyroid tumor growth, but its role in the progression of other kinds of cancer such as gastric cancer (GC) remains unknown. Accordingly, we investigated the association between XB130 expression and the prognosis of GC patien...

Full description

Bibliographic Details
Main Authors: Min Shi, Weizhen Huang, Li Lin, Dayong Zheng, Qiang Zuo, Lin Wang, Nina Wang, Yajun Wu, Yulin Liao, Wangjun Liao
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2012-01-01
Series:PLoS ONE
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/22927913/?tool=EBI
_version_ 1818458987179278336
author Min Shi
Weizhen Huang
Li Lin
Dayong Zheng
Qiang Zuo
Lin Wang
Nina Wang
Yajun Wu
Yulin Liao
Wangjun Liao
author_facet Min Shi
Weizhen Huang
Li Lin
Dayong Zheng
Qiang Zuo
Lin Wang
Nina Wang
Yajun Wu
Yulin Liao
Wangjun Liao
author_sort Min Shi
collection DOAJ
description XB130 is a newly characterized adaptor protein that was reported to promote thyroid tumor growth, but its role in the progression of other kinds of cancer such as gastric cancer (GC) remains unknown. Accordingly, we investigated the association between XB130 expression and the prognosis of GC patients. The subjects were 411 patients with GC in stages I to IV. XB130 expression was examined in surgical specimens of GC. Kaplan-Meier analysis and the Cox proportional hazards model were used to assess the prognostic significance of XB130 for survival and recurrence. Moreover, GC cells stably transfected with XB130 short hairpin RNA were established to analyze the effect of XB130 on sensitivity of chemotherapy. The results show that both XB130 mRNA and protein expression were detectable in normal gastric tissues. The overall survival time of stage IV patients and the disease-free period after radical resection of GC in stage I-III patients were significantly shorter when immunohistochemical staining for XB130 was low than when staining was high (both p<0.05). XB130 expression also predicted tumor sensitivity to several chemotherapy agents. Viability of both XB130-silenced SGC7901 cells and wild-type cells was suppressed by 5-fluorouracil (5-FU), cisplatin, and irinotecan in a dose-dependent way, but cisplatin and irinotecan were more sensitive against sXB130-silenced GC cells and 5-FU showed higher sensitivity to wild-type cells. When treated by 5-FU, patients with high expression of XB130 tumors had a higher survival rate than those with low expression tumors. These findings indicate that reduced XB130 protein expression is a prognostic biomarker for shorter survival and a higher recurrence rate in patients with GC, as well as for the response to chemotherapy.
first_indexed 2024-12-14T23:07:11Z
format Article
id doaj.art-bc6c3a812eb9423a8ba4f290e6e5c9c0
institution Directory Open Access Journal
issn 1932-6203
language English
last_indexed 2024-12-14T23:07:11Z
publishDate 2012-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj.art-bc6c3a812eb9423a8ba4f290e6e5c9c02022-12-21T22:44:18ZengPublic Library of Science (PLoS)PLoS ONE1932-62032012-01-0178e4166010.1371/journal.pone.0041660Silencing of XB130 is associated with both the prognosis and chemosensitivity of gastric cancer.Min ShiWeizhen HuangLi LinDayong ZhengQiang ZuoLin WangNina WangYajun WuYulin LiaoWangjun LiaoXB130 is a newly characterized adaptor protein that was reported to promote thyroid tumor growth, but its role in the progression of other kinds of cancer such as gastric cancer (GC) remains unknown. Accordingly, we investigated the association between XB130 expression and the prognosis of GC patients. The subjects were 411 patients with GC in stages I to IV. XB130 expression was examined in surgical specimens of GC. Kaplan-Meier analysis and the Cox proportional hazards model were used to assess the prognostic significance of XB130 for survival and recurrence. Moreover, GC cells stably transfected with XB130 short hairpin RNA were established to analyze the effect of XB130 on sensitivity of chemotherapy. The results show that both XB130 mRNA and protein expression were detectable in normal gastric tissues. The overall survival time of stage IV patients and the disease-free period after radical resection of GC in stage I-III patients were significantly shorter when immunohistochemical staining for XB130 was low than when staining was high (both p<0.05). XB130 expression also predicted tumor sensitivity to several chemotherapy agents. Viability of both XB130-silenced SGC7901 cells and wild-type cells was suppressed by 5-fluorouracil (5-FU), cisplatin, and irinotecan in a dose-dependent way, but cisplatin and irinotecan were more sensitive against sXB130-silenced GC cells and 5-FU showed higher sensitivity to wild-type cells. When treated by 5-FU, patients with high expression of XB130 tumors had a higher survival rate than those with low expression tumors. These findings indicate that reduced XB130 protein expression is a prognostic biomarker for shorter survival and a higher recurrence rate in patients with GC, as well as for the response to chemotherapy.https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/22927913/?tool=EBI
spellingShingle Min Shi
Weizhen Huang
Li Lin
Dayong Zheng
Qiang Zuo
Lin Wang
Nina Wang
Yajun Wu
Yulin Liao
Wangjun Liao
Silencing of XB130 is associated with both the prognosis and chemosensitivity of gastric cancer.
PLoS ONE
title Silencing of XB130 is associated with both the prognosis and chemosensitivity of gastric cancer.
title_full Silencing of XB130 is associated with both the prognosis and chemosensitivity of gastric cancer.
title_fullStr Silencing of XB130 is associated with both the prognosis and chemosensitivity of gastric cancer.
title_full_unstemmed Silencing of XB130 is associated with both the prognosis and chemosensitivity of gastric cancer.
title_short Silencing of XB130 is associated with both the prognosis and chemosensitivity of gastric cancer.
title_sort silencing of xb130 is associated with both the prognosis and chemosensitivity of gastric cancer
url https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/22927913/?tool=EBI
work_keys_str_mv AT minshi silencingofxb130isassociatedwithboththeprognosisandchemosensitivityofgastriccancer
AT weizhenhuang silencingofxb130isassociatedwithboththeprognosisandchemosensitivityofgastriccancer
AT lilin silencingofxb130isassociatedwithboththeprognosisandchemosensitivityofgastriccancer
AT dayongzheng silencingofxb130isassociatedwithboththeprognosisandchemosensitivityofgastriccancer
AT qiangzuo silencingofxb130isassociatedwithboththeprognosisandchemosensitivityofgastriccancer
AT linwang silencingofxb130isassociatedwithboththeprognosisandchemosensitivityofgastriccancer
AT ninawang silencingofxb130isassociatedwithboththeprognosisandchemosensitivityofgastriccancer
AT yajunwu silencingofxb130isassociatedwithboththeprognosisandchemosensitivityofgastriccancer
AT yulinliao silencingofxb130isassociatedwithboththeprognosisandchemosensitivityofgastriccancer
AT wangjunliao silencingofxb130isassociatedwithboththeprognosisandchemosensitivityofgastriccancer